Meeting
2023 ASCO Annual Meeting
C-reactive protein as a response biomarker to immune checkpoint blockade: A meta-analysis.
Authors
Alexander B Karol
Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY
Alexander B Karol , Yu Fujiwara , Tyler J D'Ovidio , Elena Baldwin , Himanshu Joshi , Deborah Blythe Doroshow , Matt D. Galsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2559)
DOI
10.1200/JCO.2023.41.16_suppl.2559
Abstract #
2559
Poster Bd #
401
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Predictive value of C reactive protein (CRP) in patients with metastatic renal cell carcinoma (mRCC) treated with pembrolizumab (pembro) and axitinib (axi).
First Author: Aitzaz Qaisar
Poster
2023 ASCO Breakthrough
Serum-based parameters as distinctive predictive biomarkers in patients with hepatocellular carcinoma undergoing curative radiation therapy.
First Author: Dong-Soo Lee
Poster
2022 ASCO Annual Meeting
Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy.
First Author: Deepak Bhamidipati
Poster
2021 Genitourinary Cancers Symposium
CDKN2A alterations as markers of immune checkpoint blockade (ICB) resistance in urothelial carcinoma (UC).
First Author: Amin Nassar